← ANALYST RATINGS · TIPRANKS
Tandem Diabetes Care (TNDM): analyst forecast and price target
Analyst consensus
Moderate Buy8 Buy6 Hold0 Sell
Ratings of 14 analysts in the last 3 months12-month forecast
Based on 14 price targets given in the last 3 months, the average target is $26.77, the highest $50.00, the lowest $18.00. The average is +64.8% from the last price of $16.24.
Analyst ratings 25
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Anthony Petrone★★★★★★★★★★#1225 · hits 54% · avg +8.5% | Mizuho Securities | $20.00 → $18.00−10.0% | Hold | +10.8% | Assigned | 13.10.26on TipRanks 07:40 | +1.2%next day −2.8% | ↗ |
| Matt Miksic★★★★★★★★★★#2645 · hits 55% · avg +3.9% | Barclays | $18.00 | Hold | +10.8% | Initiated | 07.10.26on TipRanks 03:55 | −1.7%next day −0.6% · 5 days +2.1% | ↗ |
| Name not given | — | $26.00 | Buy | +60.1% | Reiterated | 01.10.26on TipRanks Oct 2 21:45 | +1.0%next day −0.7% · 5 days −6.3% | ↗ |
| Joanne Wuensch★★★★★★★★★★#3684 · hits 55% · avg +2.3% | Citi | $24.00 → $20.00−16.7% | Hold | +23.2% | Reiterated | 30.09.26on TipRanks 06:20 | −1.4%next day +1.0% · 5 days −4.8% | ↗ |
| Frank Takkinen★★★★★★★★★★#11823 · hits 38% · avg −3.6% | Lake Street | $50.00 | Buy | +207.9% | Reiterated | 28.09.26on TipRanks 09:10 | +5.2%next day +1.1% · 5 days −0.6% | ↗ |
| AI xAi Medical - DevicesxAI Grok-3 | TipRanks - xAI | $17.00 → $15.50−8.8% | Hold | −4.6% | Reiterated | 25.09.26on TipRanks 11:05 | — | |
| AI DeepSeek Medical - DevicesDeepSeek R1-0528 | TipRanks - DeepSeek | $17.50 → $15.00−14.3% | Hold | −7.6% | Reiterated | 25.09.26on TipRanks 11:05 | — | |
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $17.00 → $15.00−11.8% | Hold | −7.6% | Reiterated | 25.09.26on TipRanks 11:05 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $16.50 → $14.50−12.1% | Sell | −10.7% | Downgrade | 25.09.26on TipRanks 11:05 | — | |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $17.50 → $15.00−14.3% | Hold | −7.6% | Reiterated | 25.09.26on TipRanks 11:05 | — | |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $16.00 → $15.00−6.2% | Hold | −7.6% | Reiterated | 25.09.26on TipRanks 11:05 | — | |
| Richard Newitter★★★★★★★★★★#1772 · hits 48% · avg +6.6% | Truist Financial | $31.00 → $28.00−9.7% | Buy | +72.4% | Assigned | 24.09.26on TipRanks 07:30 | −7.0%next day +2.7% · 5 days +8.8% | ↗ |
| Steven Lichtman★★★★★★★★★★#568 · hits 54% · avg +14.7% | William Blair | — | Buy | — | Initiated | 21.08.26on TipRanks 08:25 | −1.5%next day −0.2% · 5 days −4.5% | ↗ |
| William Plovanic★★★★★★★★★★#5377 · hits 43% · avg +1.3% | Canaccord Genuity | $40.00 | Buy | +146.3% | Reiterated | 11.08.26on TipRanks Aug 12 07:35 | +3.1%next day −0.3% · 5 days +1.6% | ↗ |
| Jonathan Block★★★★★★★★★★#2320 · hits 50% · avg +5.3% | Stifel Nicolaus | $22.00 | Hold | +35.5% | Reiterated | 07.08.26on TipRanks 14:25 | +18.5%next day +1.9% · 5 days +1.1% | ↗ |
| Travis Steed★★★★★★★★★★#3596 · hits 53% · avg +3.0% | Bank of America Securities | $25.00 | Hold | +53.9% | Reiterated | 07.08.26on TipRanks 09:07 | +18.5%next day +1.9% · 5 days +1.1% | ↗ |
| Unknown Analyst | Oppenheimer | $22.00 | Buy | +35.5% | Assigned | 07.08.26on TipRanks 08:35 | +18.5%next day +1.9% · 5 days +1.1% | ↗ |
| Matthew O'Brien★★★★★★★★★★#12031 · hits 41% · avg −4.5% | Piper Sandler | $33.00 | Buy | +103.2% | Reiterated | 07.08.26on TipRanks 08:01 | +18.5%next day +1.9% · 5 days +1.1% | ↗ |
| Patrick Wood★★★★★★★★★★#10768 · hits 50% · avg −2.1% | UBS | $18.00 | Hold | +10.8% | Reiterated | 07.08.26on TipRanks 07:15 | +18.5%next day +1.9% · 5 days +1.1% | ↗ |
| Name not given | — | $30.00 → $26.00−13.3% | Buy | +60.1% | Reiterated | 06.08.26on TipRanks Aug 7 07:06 | −3.9%next day +18.5% · 5 days +21.9% | ↗ |
| Mathew Blackman★★★★★★★★★★#2177 · hits 49% · avg +9.2% | TD Cowen | $28.00 | Buy | +72.4% | Reiterated | 06.08.26on TipRanks Aug 7 04:00 | −3.9%next day +18.5% · 5 days +21.9% | ↗ |
| Anthony Petrone★★★★★★★★★★#1225 · hits 54% · avg +8.5% | Mizuho Securities | $24.00 → $20.00−16.7% | Hold | +23.2% | Reiterated | 15.07.26on TipRanks 07:55 | −2.1%next day +7.2% · 5 days +11.6% | ↗ |
| David Roman★★★★★★★★★★#3715 · hits 53% · avg +5.3% | Goldman Sachs | $21.00 → $16.00−23.8% | Hold | −1.5% | Reiterated | 14.07.26on TipRanks Jul 15 16:35 | −4.7%next day −2.1% · 5 days +13.7% | ↗ |
| Kieran Ryan | Deutsche Bank | $15.50 | Hold | −4.6% | Initiated | 23.06.26on TipRanks Jun 24 00:07 | +1.9%next day +4.3% · 5 days +2.9% | ↗ |
| Larry Biegelsen★★★★★★★★★★#2729 · hits 53% · avg +3.8% | Wells Fargo | $21.00 → $27.00+28.6% | Buy | +66.3% | Upgrade | 01.06.26on TipRanks May 31 21:20 | +10.9%next day −2.9% · 5 days −0.9% | ↗ |
| Bruce Jackson★★★★★★★★★★#12272 · hits 38% · avg −9.8% | Benchmark Co. | — | Hold | — | Initiated | 11.05.26on TipRanks 16:25 | −0.4%next day −4.5% · 5 days −5.0% | ↗ |
| Matt Miksic★★★★★★★★★★#2645 · hits 55% · avg +3.9% | Barclays | $56.00 → $55.00−1.8% | Buy | +238.7% | Reiterated | 08.05.26on TipRanks May 10 21:20 | −17.0%next day −4.8% · 5 days −17.4% | ↗ |
| Issie Kirby★★★★★★★★★★#9228 · hits 27% · avg −2.0% | Rothschild & Co Redburn | $36.00 → $45.00+25.0% | Buy | +177.1% | Reiterated | 24.04.26on TipRanks 05:11 | −2.3%next day −2.8% · 5 days −5.6% | ↗ |
| Lee Hambright★★★★★★★★★★#10167 · hits 49% · avg −1.6% | Bernstein | — | Hold | — | Reiterated | 16.01.26on TipRanks Jan 19 12:00 | −4.2%next day +3.7% · 5 days 0.0% | ↗ |
| Jeff Johnson★★★★★★★★★★#1125 · hits 51% · avg +10.4% | Robert W. Baird | $18.00 → $30.00+66.7% | Buy | +84.7% | Upgrade | 16.12.25on TipRanks 05:30 | +2.5%next day +0.3% · 5 days −1.6% | ↗ |
| Matthew Taylor★★★★★★★★★★#1367 · hits 55% · avg +7.2% | Jefferies | $48.00 | Buy | +195.6% | Reiterated | 07.11.25on TipRanks 20:15 | −0.9%next day +6.8% · 5 days +14.3% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Tandem Diabetes Care
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $26.77 at a price of $16.31 (+64.1%); now: $26.77 at $16.24 (+64.8%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 8 | 4 | 6 | 6 |
| Buy | 5 | 4 | 2 | 7 | 6 | 6 |
| Hold | 10 | 11 | 12 | 11 | 9 | 8 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.24 (from $-0.36 to $-0.16). Last quarter: $-0.31.
Sales
Next quarter’s sales estimate — $266M (from $263M to $270M). Last quarter: $254M.
Best top-analyst consensus in the sector · Healthcare
About Tandem Diabetes Care
- CEO: John F. Sheridan
- Employees: 2,500
- 12400 High Bluff Drive, San Diego, CA, 92130, US
- www.tandemdiabetes.com
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
Data from the stock’s TipRanks forecast page, read 10 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗